Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Dis Child. 2009 Sep;94(9):681-5. doi: 10.1136/adc.2008.149880. Epub 2009 May 19.

Protecting infants against measles in England and Wales: a review.

Author information

1
HPA Centre for Infections, London NW9 5EQ, UK. gayatri.manikkavasagan@hpa.org.uk

Abstract

OBJECTIVE:

To establish the most appropriate age ranges for the use of human normal immunoglobulin and MMR vaccine as postexposure prophylaxis.

DESIGN:

Review of literature and of laboratory confirmed measles cases.

SETTING:

England and Wales and countries with a similar measles epidemiological profile.

PATIENTS:

Women of childbearing age and infants.

MAIN OUTCOME MEASURES:

The risk of measles, maternally derived measles antibody levels and the response to measles containing vaccines in infants.

RESULTS:

By 4 to 5 months of age, only 28-45% of infants born to women from highly vaccinated populations have protective levels of measles antibody. In the postvaccine era, between 74% and 80% of infants vaccinated between 6 and 9 months respond to vaccine, and around 67% have clinical protection from measles vaccination.

CONCLUSION:

This study suggests that many infants being born in the UK will become susceptible to measles before 6 months and will be able to respond to vaccine between 6 and 9 months of age. It is proposed that current guidance is changed to recommend passive immunisation with human normal immunoglobulin for most infants exposed to measles below 6 months of age. For infants aged 6 months or over exposed to measles, vaccination with MMR may be given.

PMID:
19457878
DOI:
10.1136/adc.2008.149880
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center